Nav: Home

Selexipag in pulmonary arterial hypertension: Added benefit not proven

October 06, 2016

Selexipag (trade name: Uptravi) is approved for long-term treatment of pulmonary arterial hypertension (PAH) in adults with moderate to severe symptoms. The drug can be used either as combination therapy with other blood-pressure lowering drugs or as monotherapy in patients who are not candidates for these therapies. Selexipag has been on the market in Germany since May 2016. In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether this drug has advantages or disadvantages in comparison with the appropriate comparator therapy.

The limitation of the comparator therapy to a specific drug and the subsequent division of the population in the dossier were inadequate. The only study cited by the drug manufacturer for one of its subpopulations compared selexipag with placebo. However, no added benefit can be inferred from such a comparison.

Hence the manufacturer presented no suitable data for the assessment of the added benefit of selexipag, and IQWiG concluded: An added benefit of selexipag in comparison with the appropriate comparator therapy is not proven.

Selective widening of vessels and inhibition of tissue growth

In PAH, the pulmonary artery is narrowed, and the heart has to work harder to pump oxygen-poor blood through the pulmonary artery into the lungs. The permanently increased workload of the right heart chamber decreases the body's oxygen supply. The high blood pressure (hypertension) is often caused by another heart or lung disease, e.g. by chronic obstructive pulmonary disease (COPD) or a congenital heart defect.

Selexipag aims to widen the pulmonary artery and slow down the overload of the heart. The drug is approved for long-term treatment of PAH patients who have no symptoms at rest but who have slight (WHO functional class II) or marked (WHO functional class III) limitation of physical activity. These restrictions cause symptoms such as dyspnoea, tiredness, chest pain, or dizziness. Selexipag is an option as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase-5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.

Manufacturer deviated from appropriate comparator therapy

The Federal Joint Committee (G-BA) specified individually optimized drug treatment specified by the physician under consideration of the respective approval status as appropriate comparator therapy.

The manufacturer deviated from this specification and considered only iloprost as an option of an individual drug treatment. It did also not use individual optimization.

In addition, the manufacturer distinguished between two subpopulations: Its "subpopulation a" comprised patients for whom also iloprost is not an option, and for whom therefore only watchful waiting until worsening of the PAH is available. Its "subpopulation b" comprised patients for whom iloprost is an option.

The limitation of the comparator therapy and the subsequent division of the population was inadequate. The Institute therefore used the appropriate comparator therapy specified by the G-BA, without division of the patient population, for the dossier assessment.

Study with placebo comparison unsuitable

The manufacturer cited a randomized controlled trial (GRIPHON) for its "subpopulation a", in which iloprost was not an option: At the start of the study, treatment in the intervention arm was expanded by administration of selexipag. There was no treatment expansion in the control arm; the patients received only placebo. In both treatment arms, it was not allowed to adjust the ongoing medication for treatment of the PAH. Iloprost was approved for about half of the patients included in the study (WHO functional class III), which contradicts the manufacturer's definition of its "subpopulation a".

The study only allowed a comparison of selexipag with placebo and was therefore unsuitable to draw conclusions on the added benefit of selexipag: The study design allowed individual adjustment of the PAH-specific treatment in case of worsening of the PAH. If the PAH worsened, however, the blinded and randomized treatment phase for the patient ended according to the study protocol.

G-BA decides on the extent of added benefit

The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.
-end-
More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as easily understandable information on informedhealth.org). If you would like to be informed when these documents are available, please send an e-mail to info@iqwig.de.

Institute for Quality and Efficiency in Health Care

Related Placebo Articles:

The placebo effect can mend a broken heart too, CU Boulder study shows
Feeling heartbroken from a recent breakup? Just believing you're doing something to help yourself get over your ex can influence brain regions associated with emotional regulation and lessen the perception of pain.
Successful insomnia treatment may require nothing more than a placebo
A new study published in Brain indicates that successful treatment for insomnia may not actually require complicated neurofeedback (direct training of brain functions).
Placebo and valium are equally effective for acute lower back pain in the ER
Emergency patients treated with naproxen and placebo had outcomes as good as or better than patients treated with naproxen and diazepam (trade name Valium) for acute lower back pain, according to the results of a double-blind, randomized clinical trial published last week in Annals of Emergency Medicine ('Diazepam Is No Better Than Placebo When Added to Naproxen for Acute Low Back Pain').
Evaluation of recombinant antithrombin vs. placebo in preterm preeclampsia
Researchers with the PRESERVE-1 Study Group University of Texas Health Science Center at Houston -- McGovern Medical School, Houston, Texas, and Yale School of Medicine, New Haven, Conn., present findings of a study titled Randomized double-blind placebo controlled evaluation of the safety and efficacy of recombinant Antithrombin versus placebo in preterm preeclampsia.
Exploiting the placebo effect can improve recovery of heart surgery patients
Exploiting the placebo effect significantly improved the recovery of patients undergoing heart surgery according to new research published in the open access journal BMC Medicine.
Placebo sweet spot for pain relief found in brain
Scientists have identified for the first time the region in the brain responsible for the placebo effect in pain relief.
Placebo reduces back pain -- even when patients know they're taking placebo
For patients with chronic back pain, 'open' treatment with placebo -- informing patients that they are taking an inactive pill, and why it might be helpful -- leads to reductions in pain and disability, reports a study in PAIN®, the official publication of the International Association for the Study of Pain.
Study finds knowingly taking placebo pills eases pain
This is the first study to demonstrate beneficial placebo effect for lower back pain sufferers who knew they were taking 'fake pills.' Patients who knowingly took placebos reported 30 percent less pain and 29 percent reduction in disability compared to control group.
Clinical trial tests spinal manipulation therapy for migraines
Manual-therapy randomized controlled trials (RCTs) are difficult to perform because it's challenging to conceal a placebo when patients are able to physically feel a treatment that's being delivered.
Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo
A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data (1) presented at the European Society for Medical Oncology's 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.

Related Placebo Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...